Egrifta


Indications and Reactions:

Role Indications Reactions
Primary
Lipodystrophy Acquired 54.1%
Product Used For Unknown Indication 32.5%
Hiv Infection 4.2%
Diabetes Mellitus 1.3%
Hypertension 1.2%
Lentivirus Test Positive 0.8%
Pain 0.8%
Cardiac Disorder 0.5%
Acquired Immunodeficiency Syndrome 0.5%
Back Disorder 0.5%
Depression 0.5%
Hyperlipidaemia 0.5%
Autoimmune Disorder 0.4%
Hiv Test Positive 0.4%
Lipohypertrophy 0.4%
Blood Cholesterol 0.3%
Blood Cholesterol Increased 0.3%
Exposure To Communicable Disease 0.3%
Hypogonadism 0.3%
Insomnia 0.3%
Weight Increased 13.7%
Injection Site Pain 7.9%
Injection Site Haematoma 7.5%
Diabetes Mellitus 6.2%
Paraesthesia 5.8%
Arthralgia 5.5%
Pain In Extremity 5.5%
Myocardial Infarction 5.1%
Blood Glucose Increased 4.8%
Oedema Peripheral 4.5%
Nausea 3.8%
Unevaluable Event 3.8%
Weight Decreased 3.8%
Headache 3.4%
Myalgia 3.4%
Abdominal Distension 3.1%
Pain 3.1%
Rash 3.1%
Renal Failure 3.1%
Swelling 3.1%
Secondary
Product Used For Unknown Indication 36.8%
Lipodystrophy Acquired 30.1%
Hiv Infection 6.8%
Lentivirus Test Positive 6.8%
Hypertension 3.0%
Blood Cholesterol 1.5%
Blood Cholesterol Increased 1.5%
Diabetes Mellitus 1.5%
Gastrooesophageal Reflux Disease 1.5%
Hiv Test Positive 1.5%
Hyperglycaemia 1.5%
Type 2 Diabetes Mellitus 1.5%
Acquired Immunodeficiency Syndrome 0.8%
Bronchial Hyperreactivity 0.8%
Carpal Tunnel Syndrome 0.8%
Constipation 0.8%
Depression 0.8%
Drug Toxicity Prophylaxis 0.8%
Fatigue 0.8%
Hypogonadism 0.8%
Weight Decreased 13.8%
Weight Increased 10.3%
Anogenital Dysplasia 6.9%
Colon Cancer Stage Iv 6.9%
Myocardial Infarction 6.9%
Rash 6.9%
Asthenia 3.4%
Basal Cell Carcinoma 3.4%
Blood Glucose Increased 3.4%
Breast Cancer 3.4%
Cardiac Failure Congestive 3.4%
Cardiac Valve Disease 3.4%
Cellulitis 3.4%
Chest Pain 3.4%
Headache 3.4%
Hyperglycaemia 3.4%
Hyperkeratosis 3.4%
Hypoaesthesia 3.4%
Injection Site Pruritus 3.4%
Insomnia 3.4%
Concomitant
Hepatitis C 100.0%
Sepsis 100.0%

Drug Data